| Accession |
PRJCA002488 |
| Title |
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small cell lung cancer |
| Relevance |
Medical |
| Data types |
Whole genome sequencing
Raw sequence reads
Genome sequencing
|
| Organisms |
Homo sapiens
|
| Description |
CRISPR-Cas9 system is an efficient genome editing tool but its clinical application continues to be controversial. This is a phase 1 trial on safety and feasibility of PD-1 edited T Cells via CRISPR-Cas9 on patients with advanced non-small cell lung cancer (NSCLC) after failing three or more lines of treatments. Total of 12 patients had sufficient CRISPR-Cas9 gene-edited T cells for clinical infusion and had completed the course of treatment for safety evaluation. The mean mutation frequency of off-target events was 0.06% (range 0.00-0.25%) at 18 candidate sites by next generation sequencing (NGS). All treatment-related adverse events (AEs) were grade 1/2. Gene-edited T cells and discernible T-cell receptor (TCR) diversity were detectable in peripheral blood at 8.0 to 52.0 weeks after infusion. Median progression-free survival (PFS) was 7.9 weeks (95% confidence interval [CI], 7.3 to not available [NA]) and median overall survival was 42.6 weeks (95% confidence interval [CI], 24.4 to NA). Clinical application of CRISPR-Cas9 gene-edited T cell is safe and feasible. Further investigation on clinical efficacy is warranted. (MHC-001 ClinicalTrials.gov number, NCT02793856) |
| Sample scope |
Multiisolate |
| Release date |
2020-04-16 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 32341578
|
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
|
Nature Medicine
|
10.1038/s41591-020-0840-5
|
2020
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| National Science and Technology Major Project
|
|
2017ZX09304023
|
|
|
|
| Submitter |
Su
Xiaoxing (suxiaoxing_work@foxmail.com)
|
| Organization |
BerryOncology |
| Submission date |
2020-04-04 |
